IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy
| Autor: | Felice Giangaspero, Andrea Pace, Maurizio Salvati, Antonella Arcella, Veronica Villani, Stefania Scarpino, Domenica Di Stefano, Riccardo Maurizi Enrici, Giuseppe Minniti, Gaetano Lanzetta, Claudia Scaringi, Vincenzo Esposito, Alessandro Bozzao |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Oncology Cancer Research Methyltransferase Prospective Studies Promoter Regions Genetic Prospective cohort study DNA Modification Methylases Brain Neoplasms Chemoradiotherapy Middle Aged Prognosis Isocitrate Dehydrogenase Dacarbazine Neurology DNA methylation IDH1 Female MGMT medicine.drug Adult medicine.medical_specialty Astrocytoma Young Adult Internal medicine Temozolomide medicine Humans Antineoplastic Agents Alkylating Aged Retrospective Studies Radiotherapy business.industry Tumor Suppressor Proteins DNA Methylation medicine.disease Anaplastic glioma Surgery DNA Repair Enzymes Concomitant Mutation Neurology (clinical) business Biomarkers Follow-Up Studies Anaplastic astrocytoma |
| Zdroj: | Journal of Neuro-Oncology. 118:377-383 |
| ISSN: | 1573-7373 0167-594X |
| Popis: | Several molecular markers have been proposed as predictors of outcome in patients with high grade gliomas. We report a retrospective multicenter study of 97 consecutive adult patients with anaplastic astrocytoma (AA) treated with radiation therapy (RT) plus concomitant and adjuvant temozolomide (TMZ) between October 2004 and March 2012. Correlations between the isocitrate dehydrogenase 1 (IDH1) mutation and O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with survival outcomes have been analyzed. At a median follow-up time of 46 months (range 12–89 months), median and 5-year overall survival rates were 50.5 months (95 % CI, 37.8–63.2) and 38 % (95 % CI, 25.7–50.7 %), and median and 5-year progression-free survival rates were 36 months (95 % CI, 28.5–44.0) and 22 % (95 % CI, 10–34 %), respectively. IDH1 mutation and MGMT promoter methylation were present in 54 and 60 % of evaluable patients, respectively. Multivariate Cox proportional hazards regression analysis showed that IDH1 mutation (P = 0.001), MGMT methylation (P = 0.01), age |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink